A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort
NCT ID: NCT03755726
Last Updated: 2024-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1200 participants
OBSERVATIONAL
2019-09-20
2034-09-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interrupters of VAscular daMAge in Malignant Hypertension
NCT04991077
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
NCT05732727
National Survey on Hypertension at Hospital
NCT00695266
Prognostic Value of Plasma Biomarkers Among Patients With Hypertension
NCT04107584
Microcirculation and Inflammatory Markers in Patients With Resistant, Stages 1/2 Hypertension and Normal Blood Pressure
NCT02759276
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This first prospective and multicentric registry will increase and modernize the knowledge of the disease. From these data, diagnostic and therapeutic recommendations based on solid scientific evidence could be developed.
The investigators want to first recruit 500 patients and define their prognosis at 5 years. The impact of the patient's phenotype, type and number of target organs affected will be studied.
A modern definition, adapted to these results, could be proposed. The epidemiology of the disease, the care pathways, the target organ disorders and the management carried out in the centers will be described in detail.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure
Exclusion Criteria
* Patients who cannot freely give their consent, or patients who refuse to participate
* Dialysis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier de PAU
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Romain Boulestreau
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH d'Annecy
Annecy, , France
CH de la côte Basque
Bayonne, , France
Avicenne APHP
Bobigny, , France
CHU - Hôpital St André
Bordeaux, , France
CH de Chalon sur Saone
Chalon-sur-Saône, , France
CH Métropole
Chambéry, , France
CHU de Clermont FERRAND
Clermont-Ferrand, , France
Hôpital Henri Mondor
Créteil, , France
CH de Dinard
Dinard, , France
CHU Michallon
Grenoble, , France
hôpital de Haguenau
Haguenau, , France
Pôle Santé Sud
Le Mans, , France
CH de Libourne
Libourne, , France
CHRU de Lille
Lille, , France
Clinique Vert Coteau
Marseille, , France
Hopital de la conception
Marseille, , France
CH Martigues
Martigues, , France
CHU de Montellier
Montpellier, , France
CHU - Hôpital Laennec
Nantes, , France
Hôpital Saint Joseph
Paris, , France
Hôpital Européen Georges Pompidou
Paris, , France
APHP Bichat
Paris, , France
Fondation Adolphe de Rothschild
Paris, , France
Hôpital Tenon
Paris, , France
CH de PAU
Pau, , France
CHU de Pointe à Pitre
Pitres, , France
CHU de Poitiers
Poitiers, , France
CHU de Rennes
Rennes, , France
CHU de ROUEN
Rouen, , France
Clinique sainte Clotilde
Saint-Denis, , France
CHU de St Etienne
Saint-Etienne, , France
CH de St Nazaire
Saint-Nazaire, , France
CHU de Strasbourg
Strasbourg, , France
CHU de Toulouse Rangueil
Toulouse, , France
CHU de Tours
Tours, , France
CH de Valenciennes
Valenciennes, , France
National Institute of Cardiology
Warsaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Boulestreau R, Lorthioir A, Dreau H, Persu A, Cremer A, Tharaux PL, Rubin S, Maier B, Mazighi M, Seris A, Paques M, Bonnin S, Halimi JM, Debeugny S, Gosse P; for the HAMA investigators. Baseline characteristics of the first 302 patients included for acute malignant hypertension crisis in the prospective multidisciplinary HAMA cohort. J Hypertens. 2024 Dec 1;42(12):2131-2138. doi: 10.1097/HJH.0000000000003851. Epub 2024 Oct 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHPAU2018/01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.